Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Takes Option to Commercialize Axis-Shield's HBP Sepsis Marker

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Axis-Shield said today that it has signed an agreement with Bio-Rad Laboratories for an option to commercialize heparin binding protein as a marker of severe sepsis.

Under the terms of this agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally.

Additional terms of the deal were not disclosed.

Axis-Shield said that preliminary studies evaluating HBP's ability to detect sepsis have shown "improved specificity and sensitivity compared to existing methods."

Bio-Rad and Axis-Shield previously signed a similar agreement for Axis-Shield's anti-CCP technology for the early detection of rheumatoid arthritis.

That test, which measures anti-cyclic citrullinated peptide antibodies and runs on Bio-Rad's BioPlex 2200 system, was cleared by the US Food and Drug Administration last October.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.